Biomarker testing is vital for all patients with lung cancer, especially younger individuals who have higher rates of ...

Colorectal Cancer: Patient dosing anticipated to initiate for ASPEN-CRC Phase 1b clinical trial in mid-year 2025. Safety and ...

Takeda has shot down candidates acquired in its $525 million Maverick Therapeutics takeover, blowing a hole in its oncology R ...

BioDlink, a leading global CDMO, proudly congratulates its partner Junshi Biosciences (HKEX-1877; SSE-688180), on receiving Investigational New Drug (IND) approval from the National Medical Products ...

In the recent study, Ramalingam found that people with Stage III lung cancer who had EGFR mutations had an 84% lower risk of ...

Vir Biotechnology, Inc. (Nasdaq: VIR), today provided a corporate update and reported financial results for the first quarter ended March 31, 2025.

A "productive" meeting with the FDA has given the firm confidence in its regulatory filing and commercialization plans for ST-920.

Patients with advanced non-small cell lung cancer and uncommon EGFR mutations lived almost twice as long without disease ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

BUFFALO, N.Y. — University at Buffalo medicinal chemist David Heppner has received the 2025 Philip S. Portoghese Lectureship ...

The potential of computational chemistry to revolutionise cancer treatment in Nigeria represents a paradigm shift in medical ...

Eledon Pharmaceuticals is poised to revolutionize kidney transplant care with tegoprubart, targeting a $6B market. Read why ...